EUVIMEDEUVIMED entdecken
CrossrefInfokarte

MicroRNA‐195‐5p Targets MYB to Regulate Proliferation and Malignant Metastasis in Triple‐Negative Breast Cancer via PI3K/AKT/mTOR Signaling

Kewei Tang, Site Bai, Qiang Zhou, Songlian Liu, Leilan Yin, Yajun Tong, Ling Long, Ludi Ou, Qinghua Yin

The Breast Journal · 2025-01 · 2025 (1)

DOI: 10.1155/tbj/7303173 ↗
AbstractBibliografische Angaben

Abstract

Objective To investigate the effect of microRNA‐195‐5p (miRNA‐195‐5p) on proliferation and malignant metastasis in triple‐negative breast cancer (TNBC) cells and its underlying mechanism. Methods Expression levels of miRNA‐195‐5p and MYB were determined by quantitative real‐time PCR (RT‐qPCR) in TNBC cells (MDA‐MB‐231 and BT‐549) and normal human mammary epithelial cells (MCF‐10A). Cell proliferation was assessed via CCK‐8 assays after miRNA‐195‐5p overexpression or knockdown in MDA‐MB‐231 cells. Transwell assays evaluated cellular invasion and migration. Western blotting analyzed impacts on the PI3K/AKT/mTOR pathway. Targeting of MYB by miRNA‐195‐5p was confirmed using TargetScan prediction and dual‐luciferase reporter assays. RT‐qPCR measured MYB expression upon miRNA‐195‐5p modulation. Rescue experiments (co‐overexpression of MYB and miRNA‐195‐5p) further assessed proliferation and PI3K/AKT/mTOR signaling via CCK‐8 and Western blotting. Results Compared to MCF‐10A cells, miRNA‐195‐5p expression was significantly downregulated ( p < 0.01), while MYB was markedly upregulated ( p < 0.001) in TNBC cells. Overexpression of miRNA‐195‐5p inhibited MDA‐MB‐231 proliferation, invasion, and migration; conversely, its knockdown promoted these phenotypes. MiRNA‐195‐5p directly targeted and negatively regulated MYB. MYB overexpression activated the PI3K/AKT/mTOR pathway, enhancing cell proliferation. Rescue experiments indicated that MYB upregulation counteracted the tumor‐suppressive effects of miRNA‐195‐5p and reactivated PI3K/AKT/mTOR signaling. Conclusion miRNA‐195‐5p suppresses proliferation and metastasis in TNBC by targeting MYB and inhibiting the PI3K/AKT/mTOR pathway.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →